Skip to content

Latest News

Gland Pharma gets tentative USFDA nod for blood pressure medication

Gland Pharma gets tentative USFDA nod for blood pressure medication

Gland Pharma believes that it is the only company with first to file for this product and may be eligible for 180 days of generic drug exclusivity.

Read More

​ Gland Pharma believes that it is the only company with first to file for this product and may be eligible for 180 days of generic drug exclusivity. Gland Pharma believes that it is the only company with first to file for this product and may be eligible for 180 days of generic drug exclusivity.  Moneycontrol Latest News Read More  

Gland Pharma believes that it is the only company with first to file for this product and may be eligible for 180 days of generic drug exclusivity.

Nifty up 1%, Sensex 600 points: Easing inflation, positive cues and all that fuel the rally

Nifty up 1%, Sensex 600 points: Easing inflation, positive cues and all that fuel the rally

A softer-than-expected US inflation print for October fueled hopes of the Fed pivoting its rate hike campaign, ushering gains across global markets.

Read More

​ A softer-than-expected US inflation print for October fueled hopes of the Fed pivoting its rate hike campaign, ushering gains across global markets. A softer-than-expected US inflation print for October fueled hopes of the Fed pivoting its rate hike campaign, ushering gains across global markets.  Moneycontrol Latest News Read More  

A softer-than-expected US inflation print for October fueled hopes of the Fed pivoting its rate hike campaign, ushering gains across global markets.

Capacite Infra rebounds 2% after initial shock from tepid Q2 results

Capacite Infra rebounds 2% after initial shock from tepid Q2 results

The revenue and the resultant profitability were slightly lower due to delay in tying up the non-fund based banking limits, the company said.

Read More

​ The revenue and the resultant profitability were slightly lower due to delay in tying up the non-fund based banking limits, the company said. The revenue and the resultant profitability were slightly lower due to delay in tying up the non-fund based banking limits, the company said.  Moneycontrol Latest News Read More  

The revenue and the resultant profitability were slightly lower due to delay in tying up the non-fund based banking limits, the company said.

Capacite Infra rebounds 2% after initial shock from tepid Q2 results

Capacite Infra rebounds 2% after initial shock from tepid Q2 results

The revenue and the resultant profitability were slightly lower due to delay in tying up the non-fund based banking limits, the company said.

Read More

​ The revenue and the resultant profitability were slightly lower due to delay in tying up the non-fund based banking limits, the company said. The revenue and the resultant profitability were slightly lower due to delay in tying up the non-fund based banking limits, the company said.  Moneycontrol Latest News Read More  

The revenue and the resultant profitability were slightly lower due to delay in tying up the non-fund based banking limits, the company said.

en_USEnglish
hi_INहिन्दी en_USEnglish